KENTUCKY
v.
JOHNSON
KENTUCKY
JOHNSON
494 U.S. 1046
Supreme Court of the United States (1990)
Positive Treatment
Cited by 7 cases
Opinion
Full opinion text not available for this case.
Cases With Similar Vibessemantic neighbors from the corpus
Citator
Cited By
-
Berry v. CSX Transp., Inc., 709 So. 2d 552 (Fla. 1st DCA 1998)…Green, for example, concludes that rejecting studies that are not statistically significant would be cursory and foolish. We find his explanation instructive: The Brock [Brock v. Merrell Dow Pharm., Inc., 874 F. 2d 307 (5th Cir.1989), cert. denied, 494 U.S. 1046, 110 S.Ct. 1511, 108 L.Ed.2d 646 (1990) ] decision, in ascribing wondrous powers to the concept of statistical significance, contributes to doubts that these matters are ones that reasonably can be mastered by generalist judges. Statistical signific…
-
Daubert et ux. v. Merrell Dow Pharms., Inc., 509 U.S. 579 (U.S. 1993)…S. 826 (1992); Brock v. Merrell Dow Pharmaceuticals, Inc., 874 F. 2d 307 (CA5 1989) (reversing judgment entered on jury verdict for plaintiffs because evidence regarding causation was insufficient), modified, 884 F. 2d 166 (CA5 1989), cert. denied, 494 U. S. 1046 (1990); Green 680-681. These conventional devices, rather than wholesale exclusion under an uncompromising “general acceptance” test, are the appropriate safeguards where the basis of scientific testimony meets the standards of Rule 702. Petitioner…
-
Daubert v. Merrell DOW Pharms., Inc., 951 F.2d 1128 (9th Cir. 1991)…connection between the use of the drug and the birth defects. DeLuca v. Merrell Dow Pharmaceuticals, Inc., 911 F. 2d 941 (3d Cir.1990); Brock v. Merrell Dow Pharmaceuticals, Inc., 874 F. 2d 307, modified, 884 F. 2d 166 (5th Cir.1989), cert. denied, 494 U.S. 1046, 110 S.Ct. 1511, 108 L.Ed.2d 646 (1990); Richardson v. Richardson-Merrell, Inc., 857 F. 2d 823 (D.C.Cir.1988), cert. denied, 493 U.S. 882, 110 S.Ct. 218, 107 L.Ed.2d 171 (1989); Lynch v. Merrell-National Labs., 830 F. 2d 1190 (1st Cir.1987) (opinion…
Previewing 3 of 7 citing cases — full citator treatment, depth of discussion, and citing context are member features.
Join FLexlaw to unlock all legal intelligence